# A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

> **NCT03215524** · PHASE2 · COMPLETED · sponsor: **Canadian Myeloma Research Group** · enrollment: 120 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** DCdP
- **BIOLOGICAL:** DCd+P

## Key facts

- **NCT ID:** NCT03215524
- **Lead sponsor:** Canadian Myeloma Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-25
- **Primary completion:** 2022-06-24
- **Final completion:** 2022-06-24
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03215524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03215524, "A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03215524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*